Edgar Filing: Epizyme, Inc. - Form 4

Epizyme, Inc. Form 4											
January 30, 2014											
FORM 4	UNITED	STATES			AND EX(, D.C. 20		COMMISSIO		PPROVAL 3235-0287		
Check this box if no longer				U	·			Expires:	January 31,		
subject to Section 16. Form 4 or		NGES IN SECUI	Estimated burden hou response	urs per							
Form 5 obligations may continue. <i>See</i> Instruction 1(b).	Section 17(a) of the l	Public U	tility Hol	ding Con		nge Act of 1934, of 1935 or Secti 940				
(Print or Type Respo	nses)										
1. Name and Address of Reporting Person <u>*</u> Copeland Robert A			2. Issuer Name and Ticker or Trading Symbol Epizyme, Inc. [EPZM]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
(Last)	(First) (1	Middle)	3. Date of	of Earliest T	ransaction		(Check an appreable)				
C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE			(Month/Day/Year) 01/28/2014			Director 10% Owner X Officer (give title Other (specify below) below) EVP and CSO					
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 					
CAMBRIDGE, 1	MA 02139						Person	More than One K	eporting		
(City)	(State)	(Zip)	Tab	le I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned		
	ansaction Date hth/Day/Year)		Date, if	3. Transactic Code (Instr. 8)	4. Securiti onAcquired Disposed (Instr. 3, 4	(A) or of (D) and 5) (A)		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V	Amount	or (D) Price	(Instr. 3 and 4)				
Reminder: Report or	a separate line	for each cl	ass of sec	urities bene	-	-	-				
					inform require	ation cont ed to respo ys a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not rm	SEC 1474 (9-02)		

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of	8
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities]
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)	

8 E S

(Instr. 3)	Price of Derivative Security		(Month/Day/Year)	(Instr. 8) Acquire or Disp (D) (Instr. 3 and 5)	osed of				
				Code	V (A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 31.2	01/28/2014		А	27,40	6	<u>(1)</u>	01/27/2024	Common Stock	27,406
Reporting Owners										

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Copeland Robert A C/O EPIZYME, INC. 400 TECHNOLOGY SQUARE CAMBRIDGE, MA 02139			EVP and CSO					
Signatures								
/s/ Stephen Garbacz,								

attorney-in-fact

**Signature of Reporting Person

01/30/2014 Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

This option was granted on January 28, 2014 pursuant to the Company's 2013 Stock Incentive Plan with respect to 27,406 shares of (1) Common Stock, with 25% vesting on January 28, 2015 and the remaining 75% vesting in 36 substantially equal monthly installments

thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(